T cells are the immune system’s attack cells. When they face an infection or a tumor that never goes away, they can wear down into a state called exhaustion.1PubMed. CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer Under a microscope an exhausted T cell looks ordinary, so it is recognized by the proteins it carries, especially a cluster of built-in brakes on its surface. The best-known of these brakes also appears on healthy, working T cells, which means the answer is a combination of signs rather than one telltale marker. That same combination is what today’s immunotherapy drugs are designed to target, which is why these markers show up in pathology reports and news stories.
The Surface Brakes That Mark an Exhausted T Cell
PD-1 is a protein on the T cell surface that acts like a brake, slowing the cell down when it is switched on. In exhaustion, PD-1 is the key indicator, and it is usually joined by other brakes named TIGIT, TIM-3, LAG-3 and NKG2A.2PubMed Central. T Cell Exhaustion in the Cervical Cancer Tumor Microenvironment: PD-1 Overexpression and Co-Expression with TIGIT, Tim-3, LAG-3, and NKG2A This stacking of brakes was much stronger in T cells inside cervical tumors than in the same patients’ blood.3PubMed Central. T Cell Exhaustion in the Cervical Cancer Tumor Microenvironment: PD-1 Overexpression and Co-Expression with TIGIT, Tim-3, LAG-3, and NKG2A In skin-type (squamous) cancers, T cells in the tumor showed PD-1 and LAG-3 together with signs of being constantly switched on.4PubMed Central. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors
PD-1 also appears on healthy cells because it rises normally whenever a T cell is activated. It works as a safety check that keeps a strong attack from damaging healthy tissue during a long fight. After a short infection, PD-1 falls again once the threat clears and the cell returns to normal. In exhaustion the threat never ends, so the brake stays pressed for months and the cell stays restrained.
The number of brakes helps separate healthy cells from exhausted ones. In liver cancer, T cells carrying PD-1 plus many extra brakes were linked to shorter survival.5PubMed Central. T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma But PD-1 also sat on a group of active tissue-resident T cells with few extra brakes, and these were linked to longer survival.6PubMed Central. T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma PD-1 alone on a report does not mean the T cells have given up.
It also helps to know what a report is actually measuring. A “PD-L1 positive” result on a cancer report describes a different protein: PD-L1 is the partner that sits on tumor cells or nearby immune cells and presses PD-1’s brake. A PD-L1 score is usually ordered to help decide whether a PD-1 or PD-L1 drug might help, and it is not a count of exhausted T cells. You can reasonably ask your oncologist which protein was stained, on which cells, and how the result was scored.
Why One Marker Is Never Enough
PD-1 is used as a working marker of exhaustion, while TIM-3 and KLRG-1 have been used for aged, senescent cells.7PubMed Central. T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment None of these markers belongs to only one state, so cell type is best judged by what the cell does and which genes it runs.8PubMed Central. T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment Senescence is a more final state driven by age or many past divisions, with permanent stopping of cell division.9PubMed Central. T cell senescence and exhaustion: molecular mechanisms and immune rejuvenation for cancer immunotherapy Exhausted cells keep the protective caps on their chromosomes, lack the chemical signs of aging cells, and can still die normally.10PubMed Central. T cell senescence and exhaustion: molecular mechanisms and immune rejuvenation for cancer immunotherapy
Exhaustion is also a different problem from anergy, a common mix-up. An anergic T cell was never properly switched on to begin with, while an exhausted one was switched on again and again over a long time. The two are reversed in different ways.
Function loss happens in steps, and it can end in the cells disappearing entirely.11PubMed Central. T-cell exhaustion: characteristics, causes and conversion First the cell stops multiplying well and stops making the growth signal IL-2. Next it loses the ability to make several attack chemicals at once. Late on it may make only one signal, such as interferon-gamma, and the final step can be the cell’s death. Exhausted cells also struggle to renew themselves and to remember threats they have met before.12PubMed. CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
That is why researchers confirm exhaustion by testing what the cell does, such as whether it multiplies and releases attack chemicals when shown its target. A cell can carry several brakes and still perform well, so a marker list without a function test is only a suggestion. The genes a cell is running add evidence, but they are read together with function, not in place of it.
TOX, the Inner Switch Behind Exhaustion
TOX is a protein that switches whole groups of genes on or off inside the T cell.13PubMed Central. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion Without it, exhausted T cells do not form at all, while normal fighting and memory T cells form fine.14PubMed Central. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion In chronic infections and tumors TOX is switched on quickly and stays high, whereas in short infections it rises only a little and fades.15PubMed Central. Epigenetic regulation of T cell exhaustion Once high, TOX keeps itself switched on even without its original trigger.16PubMed Central. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion That difference in timing explains why a cold doesn’t exhaust T cells but a tumor can: constant signaling for months locks TOX on and commits the cell to exhaustion.
TOX also controls the surface brakes. When it was removed from tumor-fighting T cells in mice, the cells did not raise PD-1, TIGIT, TIM-3 or CD39-type brakes.17PubMed Central. TOX is a critical regulator of tumour-specific T cell differentiation Those cells kept high levels of TCF-1, a protein linked to stem-like, renewable T cells.18PubMed Central. TOX is a critical regulator of tumour-specific T cell differentiation
You are unlikely to see TOX on a routine report. It sits inside the cell, so measuring it takes special lab staining or gene tests, and it appears mainly in research and specialized tumor studies. Surface brakes like PD-1 are easier to measure in practice.
Stem-Like and Terminally Exhausted Cells
Exhausted cells come in stages. A stem-like group can renew itself and produce the more worn-out terminal cells.19PubMed Central. Ectopic Tcf1 expression instills a stem-like program in exhausted CD8(+) T cells to enhance viral and tumor immunity The stem-like cells carry TCF-1 together with PD-1.20PubMed Central. TCF-1-centered transcriptional network drives an effector versus exhausted CD8 T cell fate decision Terminally exhausted cells carry very high PD-1 and TOX and have shut down their attack genes.21PubMed Central. Epigenetic regulation of CD8+ T cell exhaustion: recent advances and update Forcing more TCF-1 into exhausted cells produced more stem-like cells and better control of viruses and tumors in animal models.22PubMed Central. Ectopic Tcf1 expression instills a stem-like program in exhausted CD8(+) T cells to enhance viral and tumor immunity
The two stages differ in what they can do. Stem-like cells still divide and can respond when a brake is released. Terminal cells are far less useful even after a brake is lifted.
This matters for treatment because stem-like cells act as a reserve that keeps producing new fighters. Checkpoint drugs appear to work largely by drawing on that reserve, so the drug needs those cells to still be there. A tumor with few of them may respond less well because there is little to reawaken. Researchers therefore look at TCF-1 alongside PD-1 when asking whether treatment might help.
Energy failure pushes cells toward the terminal stage. As stem-like cells become fully exhausted, their mitochondria, the cell’s power plants, decline sharply.23PubMed Central. Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1α-mediated glycolytic reprogramming The cells switch to a less efficient way of burning sugar and build up damaging oxygen byproducts.24PubMed Central. Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1α-mediated glycolytic reprogramming In mice, weakening mitochondria alone was enough to start the exhaustion program, so energy failure is a cause, not just a result.25PubMed Central. Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1α-mediated glycolytic reprogramming Exhausted cells show swollen, poorly charged mitochondria that can’t produce energy well.26PubMed Central. Mitochondrial Metabolism in T-Cell Exhaustion
Can Exhaustion Be Reversed
Exhausted cells pack their DNA in a distinct way that decides which genes they can use.27PubMed Central. Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in humans In people cured of hepatitis C, and in HIV, this pattern changed only a little after the infection was controlled.28PubMed Central. Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in humans Features around the TOX gene stayed “scarred” long after the cause was gone.29PubMed Central. Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in humans
The scar is not damage to the DNA code. What changes is which stretches of DNA are tightly wound and unreadable. An attack gene wound tight stays off even when conditions improve.
So removing the brake signal or clearing the tumor often isn’t enough to fully restore terminally exhausted cells.30PubMed Central. Epigenetic regulation of CD8+ T cell exhaustion: recent advances and update Stem-like exhausted cells keep some of their DNA open, which leaves them some room to recover.31PubMed Central. Epigenetic regulation of CD8+ T cell exhaustion: recent advances and update
For someone after a cured infection, this means the specific T cells exhausted by the virus may not fully recover. The immune system makes new T cells over time, and those are not scarred. This is an active research question, not a reason for alarm.
How Markers Guide Immunotherapy
Checkpoint drugs are antibodies that block brake proteins such as PD-1 so T cells can attack again. These drugs are usually given by infusion into a vein on a repeating schedule set by the care team. They don’t attack the cancer themselves; they free the patient’s own T cells to do so.
Some drugs block PD-1 on the T cell and others block PD-L1 on the tumor side. A patient may hear either name depending on the drug chosen.
Combining PD-1 blockade with blockade of CTLA-4, TIM-3, LAG-3 or TIGIT can work better than a single block.32PubMed Central. Reversing T-cell Dysfunction and Exhaustion in Cancer In mice, blocking TIM-3 plus the PD-1 pathway made tumors disappear completely in half the animals, which then resisted new tumors.33PubMed Central. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity In lymphoma cells, blocking LAG-3 or PD-1 alone did little, while blocking both raised the cells’ attack signals.34PubMed Central. Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma
If you are facing treatment, useful questions are which brake your drug blocks (PD-1, PD-L1, CTLA-4 or LAG-3), whether your tumor was tested for PD-L1 or similar markers, and whether a combination of two checkpoint drugs is an option for your cancer. Combinations can bring more immune side effects, so ask what to watch for.
CAR-T cells are a patient’s own T cells re-engineered to attack cancer, and they can be built to resist exhaustion. Adding extra c-JUN made them resistant to exhaustion, with less PD-1 and CD39.35PubMed Central. Counteracting CAR T cell dysfunction A 4-1BB signaling part in the design reduces exhaustion caused by constant background signaling.36PubMed Central. Making Potent CAR T Cells Using Genetic Engineering and Synergistic Agents
Other Markers You May See Named
CD39 is an enzyme that, with CD73, turns the energy molecule ATP into adenosine, which suppresses immune attack around tumors.37PubMed Central. CD39 Regulation and Functions in T Cells It often appears alongside PD-1 on exhausted cells, so the two together are one more clue, though still not proof without a function test.
In helper (CD4) T cells, terminal exhaustion is marked by CD39 rather than TIM-3.38PubMed Central. CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer? CD4 cells carrying CD39 had more PD-1 and made fewer immune signals.39PubMed Central. CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer?
Helper T cells can exhaust under constant exposure, with PD-1, CTLA-4 and suppressive signals like IL-10.40Cancer Biology & Medicine. The mechanisms and clinical significance of CD8+ T cell exhaustion in anti-tumor immunity They then give less support to antibody-making cells and killer T cells.41Cancer Biology & Medicine. The mechanisms and clinical significance of CD8+ T cell exhaustion in anti-tumor immunity In people with HIV and hepatitis C whose immune counts didn’t recover on treatment, helper cells were exhausted while killer cells carried brakes but still worked.42Russian Journal of Infection and Immunity. Markers of CD4⁺ AND CD8⁺ T-cell exhaustion in hiv/hcv coinfected immunological non-responders to antiretroviral therapy Markers like TIM-3 don’t carry over neatly from killer cells, so a report focused only on killer T cells can miss part of the picture.
Blood and gene tests are emerging. In melanoma patients on PD-1 drugs, those whose cancer grew had about twice the blood level of a free-floating LAG-3 before treatment, around 186 versus 85 pg/ml.43PubMed Central. Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients Gene scores built from exhaustion markers like PD-1, TOX, TIGIT and LAG-3 can sort tumors into high and low exhaustion, with high exhaustion tied to worse outlook.44PubMed Central. Prioritizing exhausted T cell marker genes highlights immune subtypes in pan-cancer These are research tools, not standard tests most patients will receive.
Gut bacteria products such as butyrate can lower PD-1 on killer T cells in lab dishes.45PubMed Central. Spatial microbiome-metabolic crosstalk drives CD8+ T-cell exhaustion through the butyrate-HDAC axis in colorectal cancer That doesn’t show a diet cures exhaustion, and any supplements are worth discussing with your care team before treatment.